Literature DB >> 11933820

Somatuline Autogel: an extended release lanreotide formulation.

Stafford Lightman1.   

Abstract

Somatuline Autogel provides effective control of growth hormone levels and is at least as effective as intramuscular Somatuline LA. Somatuline Autogel has a first order kinetic profile providing at least 28 days' efficacy with reduced burst release and a more consistent drug release over the dose period. The product is presented in a pre-filled syringe and is given deep subcutaneously.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11933820     DOI: 10.12968/hosp.2002.63.3.2062

Source DB:  PubMed          Journal:  Hosp Med        ISSN: 1462-3935


  9 in total

Review 1.  Antitumor effects of somatostatin analogs in neuroendocrine tumors.

Authors:  Lucas Sidéris; Pierre Dubé; Anja Rinke
Journal:  Oncologist       Date:  2012-05-24

2.  Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency.

Authors:  Brian Tomlinson; Neil G Thomas; Irene W Lan; Manuel Barbanoj; Rosa M Antonijoan; Eva Drazna; Joaquim Ramis; Rosendo Obach; Concepción Peraire
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.

Authors:  Iñaki F Trocóniz; Josep-María Cendrós; Concepción Peraire; Joaquim Ramis; Maria J Garrido; Paolo F Boscani; Rosendo Obach
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Management of acromegaly: is there a role for primary medical therapy?

Authors:  Zachary M Bush; Mary Lee Vance
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 5.  Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Venkata K Pokuri; Mei Ka Fong; Renuka Iyer
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.075

Review 6.  Pharmacological therapy for acromegaly: a critical review.

Authors:  Alex F Muller; Aart Jan Van Der Lely
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  The expanding role of somatostatin analogs in the management of neuroendocrine tumors.

Authors:  Edward M Wolin
Journal:  Gastrointest Cancer Res       Date:  2012-09

8.  Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.

Authors:  T Lucas; R Astorga
Journal:  Clin Endocrinol (Oxf)       Date:  2006-09       Impact factor: 3.478

Review 9.  New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.

Authors:  Esther Una Cidon
Journal:  World J Gastrointest Oncol       Date:  2017-01-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.